JAK inhibitors and black box warnings: what is the future for JAK inhibitors?

Tokareva, Kate; Reid, Pankti; Yang, Victor; Liew, David; Peterson, Alexander C.; Baraff, Aaron; Giles, Jon; Singh, Namrata

doi:10.1080/1744666x.2023.2249237

Cited by 8 publications

(3 citation statements)

References 93 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 17 32 91 97 108 109 ] This association was observed in data from the oral surveillance program that identified an increased risk of VTE in old patients with RA and multiple cardiac risk factors treated with tofacitinib. [ 109 ] Accordingly, various authorities recommend avoiding use of JAK inhibitors in this patient population. [ 17 32 91 97 108 109 ]…”

Section: Patient and Disease Characteristicsmentioning

confidence: 91%

See 1 more Smart Citation

Selecting first-line advanced therapy for ulcerative colitis: A clinical application of personalized medicine

Mukhtar,

Mosli

2024

Saudi Journal of Gastroenterology

View full text Add to dashboard Cite

Ulcerative colitis (UC) is a chronic autoimmune inflammatory disease that affects the colon, leading to symptoms of bloody diarrhea, abdominal cramps, and urgency. The treatment of UC has evolved over the past few decades from locally active anti-inflammatory compounds to more selective therapies that target specific arrays of the immune system. The challenge of selecting the first advanced therapy became apparent in this rapidly expanding landscape of medications. No current investigational tools, such as genetic, immunologic, or biological markers, can guide the identification of the safest and most effective therapeutic option for each patient. Hence, physicians must carefully assess patient/disease characteristics and match them with the most suitable drug through a clinically driven assessment. In this paper, we outline patient and drug characteristics that play a role in selecting first-line advanced therapies for UC and propose an algorithm for selection.

show abstract

Section: Patient and Disease Characteristicsmentioning

confidence: 91%

“…[ 109 ] Accordingly, various authorities recommend avoiding use of JAK inhibitors in this patient population. [ 17 32 91 97 108 109 ]…”

Section: Patient and Disease Characteristicsmentioning

confidence: 99%

Selecting first-line advanced therapy for ulcerative colitis: A clinical application of personalized medicine

Mukhtar,

Mosli

2024

Saudi Journal of Gastroenterology

View full text Add to dashboard Cite

show abstract

“…In September 2021, the Food and Drug Administration (FDA) reviewed the post-marketing safety trial results comparing tofacitinib with anti-TNF in rheumatoid arthritis (RA), and concluded that tofacitinib posed a higher risk of major cardiovascular events (MACE), thromboembolic events, malignant neoplasms, and death. Based on these results, a boxed warning was issued, which also extended to other JAKi [ 8 , 9 ].…”

Section: Introductionmentioning

confidence: 99%

Biologics Versus JAK Inhibitors. Part I: Cancer Risk. A Narrative Review

Mansilla-Polo,

Morgado-Carrasco

2024

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Introduction Biological drugs (BD) and Janus kinase inhibitors (JAKi) have revolutionized the treatment of diverse dermatoses. However, there are concerns regarding their safety, especially the risk of cancer and opportunistic infections. Here, we discuss the risk of cancer associated with the BD and JAKi used in dermatology. Methods A narrative review was carried out. All relevant articles evaluating the risk of cancer associated with BD or JAKi and published between January 2010 and February 2024 were selected. Results Multiple large studies have evaluated the association between BD, JAKi and cancer risk. However, there is a lack of prospective, comparative studies. Overall, patients undergoing BD and JAKi present a cutaneous cancer incidence similar to that in the general population. The drugs more strongly associated with non-skin cancer risk were anti-tumor necrosis factor (anti-TNFs) agents and JAKi (especially tofacitinib and oral ruxolitinib). This risk appears to increase with age, the presence of other factors (such as chronic immunosuppression from previous drugs or other comorbidities), and specific diseases such as rheumatoid arthritis (RA) and myelodysplastic syndrome. Conversely, BD such as interleukin (IL)-17 and IL-23 inhibitors may even reduce the risk of some visceral and hematological malignancies. In patients with dermatological conditions such as psoriasis and atopic dermatitis, the risk of malignancies may be lower than in other subgroups, and probably comparable to the general population. Conclusions The incidence of cancer in patients undergoing BD or JAKi is generally low. This incidence can be higher in elderly patients with RA or myelodysplastic syndrome, and in those undergoing prolonged therapy with tofacitinib or ruxolitinib (oral), or anti-TNF agents.

show abstract

Pharmaceutical aspects of JAK inhibitors: a comparative review

Jinesh,

Radhakrishnan

2024

Inflammopharmacol

View full text Add to dashboard Cite

JAK inhibitors and black box warnings: what is the future for JAK inhibitors?

Cited by 8 publications

References 93 publications

Selecting first-line advanced therapy for ulcerative colitis: A clinical application of personalized medicine

Selecting first-line advanced therapy for ulcerative colitis: A clinical application of personalized medicine

Biologics Versus JAK Inhibitors. Part I: Cancer Risk. A Narrative Review

Pharmaceutical aspects of JAK inhibitors: a comparative review

Contact Info

Product

Resources

About